Corticotropin-releasing factor receptor type 2

Corticotropin-releasing factor receptor type 2 or corticotropin-releasing hormone receptor 2 or CRFR2 or CRHR2 or CRF2 or CRF2 or CRH2 is a protein but CRFR2 may also refer to the gene that encodes the protein.

ME/CFS

CRFR2 may be upregulated in ME/CFS patients - although this has not yet been proven - and the degree of upregulation may be linked to the severity of ME/CFS. The new drug CT38 is currently in clinical trials at the Bateman Horne Center to determine if downregulating CRFR2 is an effective treatment or cure for ME/CFS.

Notable studies

• 2021, Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (Full text)

See also

• CRFR2 upregulation hypothesis
• CT38
• InTiME trial
• Long COVID

Learn more

• Sep 2021, Cortene Weighs-In on Future Plans for CT38 - Bateman Horne Center
• Sep 2021, Cortene study published
• Sep 2021, Dr Bateman on Cortene and CT38

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.